The statistical analysis of OS based on 6 RCTs revealed that the PD-1/PD-L1 inhibitor significantly improved the OS of cancer patients compared with the control (HR, 0.69; 95% CI 0.62 to 0.76) (Figure 2B). The gene discussed is CD274; the disease is cancer.